Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 41Other hematologic neoplasm 27Gastrointestinal 27Thoracic 20Plasma cell 14Gynecologic 13Myeloid 12Sarcoma 11Head & Neck 11Genitourinary 11CNS 11Dermatologic 8Endocrine 7Other neoplasm 5NET 5Breast 4Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Advanced Solid Tumors 481Solid Tumor 418Advanced Solid Tumor 409Unspecified Adult Solid Tumor, Protocol Specific 350Solid Tumors 322Mesothelioma, Malignant 281Mesothelioma 244Solid Tumor, Adult 113Carcinoma, Non-Small-Cell Lung 109Retinoblastoma 81Ovarian Neoplasms 65Lung Neoplasms 61Melanoma 56Sarcoma 52Stomach Neoplasms 50Carcinoma, Renal Cell 49Colorectal Neoplasms 46Small Cell Lung Carcinoma 45Pancreatic Neoplasms 45Esophageal Neoplasms 45Neoplasms 43Uterine Cervical Neoplasms 41Breast Neoplasms 38Advanced or Metastatic Solid Tumors 35Hematopoietic and Lymphatic System Neoplasm 34Neoplasm Metastasis 33Squamous Cell Carcinoma of Head and Neck 32Advanced Malignant Solid Tumors 31Solid Tumours 30Triple Negative Breast Neoplasms 29

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms by Histologic Type × Other solid neoplasm × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡